MSAM
MRNA icon

Moloney Securities Asset Management’s Moderna MRNA Stock Holding History

Moloney Securities Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,575
Closed -$1.23M – 519
2025
Q2 		$1.23M Sell
44,575
-5,575
-11% -$147K 0.15% 161
2025
Q1 		$1.42M Buy
50,150
+45,296
+933% +$1.61M 0.19% 131
2024
Q4 		$202K Sell
4,854
-5,406
-53% -$258K 0.03% 416
2024
Q3 		$686K Buy
10,260
+4,419
+76% +$406K 0.09% 238
2024
Q2 		$694K Sell
5,841
-4,704
-45% -$595K 0.1% 222
2024
Q1 		$1.12M Buy
10,545
+2,734
+35% +$276K 0.17% 147
2023
Q4 		$777K Buy
7,811
+1,850
+31% +$156K 0.12% 194
2023
Q3 		$616K Sell
5,961
-113
-2% -$12.6K 0.11% 209
2023
Q2 		$738K Sell
6,074
-3,882
-39% -$518K 0.13% 188
2023
Q1 		$1.53M Sell
9,956
-2,423
-20% -$400K 0.28% 95
2022
Q4 		$2.22M Buy
12,379
+718
+6% +$117K 0.49% 53
2022
Q3 		$1.38M Buy
11,661
+775
+7% +$118K 0.33% 78
2022
Q2 		$1.55M Sell
10,886
-4,450
-29% -$636K 0.36% 77
2022
Q1 		$2.64M Buy
15,336
+1,968
+15% +$331K 0.51% 50
2021
Q4 		$3.4M Buy
13,368
+125
+0.9% +$36.5K 0.58% 38
2021
Q3 		$5.1M Sell
13,243
-4,620
-26% -$1.7M 0.93% 20
2021
Q2 		$4.2M Buy
17,863
+7,375
+70% +$1.32M 0.76% 28
2021
Q1 		$1.37M Buy
10,488
+815
+8% +$118K 0.27% 98
2020
Q4 		$1.01M Sell
9,673
-412
-4% -$41.7K 0.22% 120
2020
Q3 		$714K Sell
10,085
-10,325
-51% -$720K 0.19% 135
2020
Q2 		$1.31M Sell
20,410
-15,155
-43% -$830K 0.38% 85
2020
Q1 		$1.06M Sell
35,565
-635
-2% -$14.6K 0.38% 82
2019
Q4 		$708K Sell
36,200
-102,750
-74% -$1.82M 0.22% 131
2019
Q3 		$2.21M Buy
138,950
+83,875
+152% +$1.24M 0.74% 33
2019
Q2 		$806K Buy
55,075
+3,437
+7% +$73.8K 0.27% 116
2019
Q1 		$1.05M Buy
+51,638
New +$958K 0.36% 81

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Moloney Securities Asset Management's MRNA Position: Q3 2025 in Review

Moloney Securities Asset Management sold out of Moderna (MRNA) in Q3 2025, closing a stake of 44,575 shares — an estimated $1.23M sold.

Moloney Securities Asset Management first reported a position in MRNA in Q1 2019 and held it in 26 quarters. The position peaked at $5.1M in Q3 2021. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Moloney Securities Asset Management reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Moloney Securities Asset Management sold 44,575 Moderna shares in Q3 2025, an estimated $1.23M.
  • Moloney Securities Asset Management first reported a position in Moderna in Q1 2019 and held it in 26 quarters.
  • Moloney Securities Asset Management's Moderna position peaked at $5.1M in Q3 2021.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.